Inductos (Dibotermin Alfa)

Dibotermin alfa mimics the natural bone morphogenetic protein‑2. After implantation, it binds to BMP receptors on local mesenchymal cells, activating SMAD signaling pathways. This triggers expression of osteogenic genes, causing stem cells to differentiate into osteoblasts that lay down extracellular matrix and mineralize, resulting in new bone at the target site.

The dose of Inductos is determined by the operating surgeon based on the size of the bone defect, the specific surgical indication, and clinical guidelines. No fixed dosing regimen is provided in the product information; the prescriber selects the appropriate amount for each patient.

Safety of dibotermin alfa in pregnancy and lactation has not been established, and the product carries an unknown pregnancy category. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only after careful consideration by the treating physician.

To request Inductos, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Inductos delivers the same recombinant human BMP‑2 protein as other BMP‑2 implants, but formulation, carrier matrix and packaging may differ. Clinical efficacy is comparable when used according to approved indications. Differences can arise in handling characteristics, storage requirements, and regulatory status in specific regions, so clinicians should review the product dossier for each option.

Inductos must be stored at 2‑8 °C. Keep the product refrigerated in its original packaging, protect it from light, and avoid freezing or shaking. Prior to use, handle the implant under aseptic conditions and allow it to equilibrate to room temperature only as directed by the surgical protocol.

Inductos is supplied as a sterile implant that the surgeon places directly into the surgical site during the procedure. It is not given systemically; the implant remains at the target location to release BMP‑2 locally and stimulate bone formation.

Serious risks include ectopic bone formation in surrounding soft tissues, which may require additional surgery; severe infection or osteomyelitis at the implantation site; and allergic or hypersensitivity reactions that can lead to anaphylaxis. Patients should be monitored closely for these events during the postoperative period.

Inductos should be avoided in patients with active infection at the intended implantation site, known hypersensitivity to dibotermin alfa or any component of the carrier matrix, malignancy in the area to be treated, or in individuals where the benefit of bone growth does not outweigh potential risks, such as certain pediatric cases without established safety data.